Evotec Brings Project in Neuropathic Pain into Clinical Development in its Alliance with Boehringer Ingelheim
Evotec receives EUR 2.0 million milestone payment from Boehringer Ingelheim
20-May-2010 -
Evotec AG announced that a compound in its strategic alliance with Boehringer Ingelheim has advanced into clinical trials. With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR 2.0 million. The compound, which was discovered and ...
Boehringer Ingelheim
clinical trials
drug discovery collaborations
+6